Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Thyroid Eye Disease (TED) Market Growth Potential: How Will Market Size Change Through 2030?
The market for thyroid eye disease (ted) has experienced robust expansion recently, projected to increase from $2.29 billion in 2025 to $2.44 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. This past growth trajectory is a consequence of several factors, including a rise in the incidence of autoimmune thyroid conditions, enhanced diagnostic awareness of ted manifestations, greater adoption of corticosteroid treatments, the expansion of eye care services, and an uptick in patient referrals from endocrinology practices.
The market for thyroid eye disease (ted) is poised for substantial advancement in the upcoming years, projected to reach $3.12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.3%. This anticipated expansion is fueled by several key factors, including the wider acceptance of innovative biologic treatments like teprotumumab, augmented funding for research into autoimmune conditions, the proliferation of less invasive surgical procedures, a greater emphasis on improving patients’ quality of life, and a growing need for individualized ted treatment plans. Throughout the forecast horizon, prominent developments are expected to include a greater embrace of specific biologic therapies, increased application of combined treatment strategies, a heightened focus on intervening in the early stages of the disease, the broadening of specialized eye care services, and the refinement of patient-centric therapeutic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp
Thyroid Eye Disease (TED) Market Industry Drivers: What Is Driving Revenue Growth?
The increasing prevalence of thyroid-related ailments is anticipated to be a primary catalyst for the expansion of the thyroid eye disease (TED) market. Thyroid disorders encompass a range of conditions impacting the thyroid gland’s functionality, leading to hormonal dysregulation and manifesting as issues like hypothyroidism, hyperthyroidism, goiter, and indeed, thyroid eye disease. Several factors contribute to this rise, including elevated iodine consumption, the presence of autoimmune diseases, inherent genetic susceptibilities, and heightened public awareness coupled with more accurate diagnostic processes. Thyroid Eye Disease (TED) itself plays a role in the overall increase in thyroid disorder statistics, being a frequent and severe complication of Graves’ disease, thereby amplifying both the collective impact and recognition of thyroid-related health concerns. As an illustration, by May 2024, projections from the Canadian Cancer Society indicated that approximately 6,600 individuals in Canada would be diagnosed with thyroid cancer in 2024, with an estimated 280 deaths foreseen. Consequently, the growing incidence of thyroid disorders is directly fueling the market’s progression in the realm of thyroid eye disease (TED).
Thyroid Eye Disease (TED) Market Segment Analysis: What Are The Major Market Categories?
The thyroid eye disease (ted) market covered in this report is segmented –
1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical
2) By Disease Severity: Mild, Moderate, Severe
3) By Drug Type: Biologics, Small Molecules, Other Drug Types
4) By Route Of Administration: Oral, Intravenous, Subcutaneous
5) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications
2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery
3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery
#Thyroid Eye Disease (TED) Market Growth Trends: What Is Influencing The Future Outlook?
Enterprises active within the thyroid eye disease (TED) market are prioritizing the creation of novel therapeutics, notably monoclonal antibody-based treatments, to engineer more potent and precise interventions aimed at mitigating inflammation, alleviating proptosis, and ultimately elevating patient well-being. These monoclonal antibody therapies involve the utilization of antibodies manufactured artificially, engineered to replicate the immune system’s capacity for identifying and neutralizing particular disease agents or aberrant cells. A prime example of this innovation occurred in September 2024 when Amgen Inc., a prominent American biotechnology firm, revealed that the Japanese Ministry of Health, Labour and Welfare (MHLW) granted approval for TEPEZZA (teprotumumab) as a treatment for active thyroid eye disease (TED), a rare and potentially vision-jeopardizing autoimmune condition. This groundbreaking medication holds the distinction of being the inaugural and sole FDA-endorsed therapy specifically developed for TED, presenting a focused therapeutic approach that effectively diminishes inflammation, swelling, and other incapacitating symptoms linked to the disorder. This regulatory milestone is of considerable significance for individuals in Japan, furnishing them with a novel and efficacious avenue for managing TED—a condition characterized by its rarity, progressive nature, and the resultant distressing eye protrusion, visual disturbances, and ocular discomfort.
Thyroid Eye Disease (TED) Market Leading Companies Driving Competitive Growth
Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann‑La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation
Access The Complete Thyroid Eye Disease (TED) Market Report:
https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report
Thyroid Eye Disease (TED) Market Geographic Distribution And Regional Opportunities
North Americawas the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (ted) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
